What is Zacks Research’s Estimate for Hologic Q1 Earnings?

Hologic, Inc. (NASDAQ:HOLX) – Equities researchers at Zacks Research decreased their Q1 2025 EPS estimates for shares of Hologic in a research report issued to clients and investors on Tuesday, December 31st. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $1.01 per share for the quarter, down from their prior estimate of $1.02. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s Q2 2025 earnings at $1.06 EPS, FY2025 earnings at $4.28 EPS, Q1 2026 earnings at $1.12 EPS, Q2 2026 earnings at $1.14 EPS, Q4 2026 earnings at $1.20 EPS, FY2026 earnings at $4.63 EPS, Q1 2027 earnings at $1.12 EPS and FY2027 earnings at $4.99 EPS.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same period in the prior year, the company posted $0.89 earnings per share. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis.

HOLX has been the topic of a number of other research reports. UBS Group upped their price objective on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Royal Bank of Canada upped their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Thursday, December 19th. Jefferies Financial Group assumed coverage on shares of Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price on the stock. Finally, JPMorgan Chase & Co. lifted their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.50.

Hologic Stock Performance

Shares of HOLX stock opened at $71.74 on Friday. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The stock has a 50 day simple moving average of $76.87 and a 200-day simple moving average of $78.43. The company has a market cap of $16.28 billion, a price-to-earnings ratio of 21.54, a price-to-earnings-growth ratio of 2.32 and a beta of 0.96. Hologic has a 12-month low of $70.36 and a 12-month high of $84.67.

Institutional Investors Weigh In On Hologic

Several hedge funds have recently modified their holdings of HOLX. State Street Corp raised its position in shares of Hologic by 0.8% in the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock valued at $847,944,000 after buying an additional 81,057 shares during the last quarter. FMR LLC raised its holdings in Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after acquiring an additional 2,174,093 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Hologic by 0.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock worth $208,051,000 after purchasing an additional 18,774 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Hologic by 8.6% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock worth $200,952,000 after purchasing an additional 195,285 shares during the last quarter. Finally, Black Creek Investment Management Inc. increased its stake in Hologic by 60.9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after purchasing an additional 885,524 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.75% of the stock is owned by corporate insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.